European Commission Grants Approval of OGSIVEO(R) (nirogacestat) for the Treatment of Adults with Desmoid Tumors
(NASDAQ:SWTX), STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO(R) (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is […]